Evaluation of the safety and tolerability profile of Sativex ®: Is it reassuring enough?

Expert Review of Neurotherapeutics

Volumn 12, Issue 4 SUPPL., 2012, Pages 9-14

  Wade, Derick ^a  

^a OXFORD CENTRE FOR ENABLEMENT   (United Kingdom)

Author keywords

multiple sclerosis; nabiximols; safety; Sativex ; spasticity; tolerability

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL; ILLICIT DRUG; NABIXIMOLS;

ATTENTION DISTURBANCE; BALANCE DISORDER; CONCENTRATION LOSS; CONFERENCE PAPER; DEPRESSION; DISORIENTATION; DISSOCIATIVE DISORDER; DIZZINESS; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG INFORMATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DRUNKENNESS; EUPHORIA; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; LONG TERM CARE; MEMORY DISORDER; MENTAL DISEASE; MULTIPLE SCLEROSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; SPASTICITY; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

CLINICAL TRIALS AS TOPIC; DRUG TOLERANCE; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PLANT EXTRACTS; PSYCHOTROPIC DRUGS;

EID: 84860162121     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.12     Document Type: Conference Paper

References (23)

1. Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict. Sci. Clin. Pract. 4, 4-16 (2007).
2. Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature. Am. J. Addict. 16, 331-342 (2007). (Pubitemid 47450754)
3. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 369, 1047-1053 (2007). (Pubitemid 46436128)
4. Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 23, 543-553 (2009).
5. Cooper ZD, Haney M. Actions of delta-9- tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. Int. Rev. Psychiatry 21, 104-112 (2009).
6. Mechoulam R. Marihuana chemistry. Science 168, 1159-1163 (1970).
7. Devane WA, Dysarz FA, Johnson MR et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605-613 (1988). (Pubitemid 19007296)
8. Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today 42, 495-501 (2006).
9. Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of delta-9-THC and cannabidiol on nocturnal sleep and early morning behaviour in young adults. J. Clin. Psychopharmacol. 24, 305-313 (2004). (Pubitemid 38658039)
10. Stott CG, Wright S, Guy GW. A comparison of pharmacokinetic profiles of inhaled delta-9-tetrahydrocannabinol (THC) from smoked cannabis with Sativex® oromucosal spray in humans: implications for possible symptomatic treatment in multiple sclerosis. Eur. J. Neurol. 15(Suppl. 3), 365 (2008).
11. Constantinescu CS, Sarantis N. Long-term open-label treatment with Sativex® in patients with multiple sclerosis. Mult. Scler. 12, S111 (2006).
12. Sativex® integrated safety analysis, 2007. Data on file, GW Pharma.
13. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 12, 639-645 (2006). (Pubitemid 46940638)
14. Collin C, Serpell M, Potts R. Results of an open-label extension trial of Sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity. Mult. Scler. 13, S129 (2007).
15. Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who were receiving long term Sativex® (nabiximols). Mult. Scler. 18(2), 219-228 (2011).
16. Novotna A, Mares J, Ratcliffe S et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18, 1122-1131 (2011).
17. Collin C, Ehler E, Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 32, 451-459 (2010).
18. Robson P. Abuse potential and psychoactive effects of δ-9- tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin. Drug Saf. 10, 675-685 (2011).
19. Aragona M, Onesti E, Tomassini V et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin. Neuropharmacol. 32, 41-47 (2009).
20. Schoedel K, Chen N, Hilliard A et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum. Psychopharmacol. doi:10.1002/hup.1196 (2011) (Epub ahead of print).
21. Wade D, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 10, 434-441 (2004). (Pubitemid 39117341)
22. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database of Syst. Rev. 2, CD001332 (2004).
23. Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study. Expert Rev. Pharmacoecon. Outcomes Res. 11, 205-213 (2011).